Financial Performance - Aura Biosciences reported a net loss of $27.5 million for Q1 2025, compared to a net loss of $19.7 million for Q1 2024, reflecting an increase of approximately 39% year-over-year [21]. - The comprehensive loss for Q1 2025 was $27.6 million, compared to $20.2 million in Q1 2024 [24]. - General and administrative expenses increased to $5.7 million in Q1 2025 from $5.3 million in Q1 2024, driven by higher personnel costs [21]. Research and Development - Research and development expenses rose to $23.3 million in Q1 2025 from $17.1 million in Q1 2024, primarily due to ongoing clinical trial costs [17]. - The ongoing Phase 1b/2 trial for NMIBC will evaluate bel-sar in approximately 26 patients, with initial efficacy data expected by year-end 2025 [12]. - The CoMpass trial for early-stage choroidal melanoma has enrolled over 220 patients in a pre-screening tool since June 2024, with completion expected by the end of 2025 [4]. - The company expects initial data from the Phase 2 trial for metastases to the choroid in 2025, with a focus on a basket study approach [7]. - Bel-sar is being explored for three ocular oncology indications, collectively affecting over 60,000 patients annually in the U.S. and Europe [6]. - The company has filed a patent application for a new formulation of bel-sar for bladder cancer, aimed at enhancing in-office urologist procedures [10]. Financial Position - As of March 31, 2025, the company had cash and cash equivalents totaling $128.0 million, sufficient to fund operations into the second half of 2026 [17]. - Total assets decreased from $182,503 million as of December 31, 2024, to $155,401 million as of March 31, 2025, representing a decline of approximately 14.85% [26]. - Total current assets decreased from $160,623 million to $134,517 million, a reduction of about 16.26% [26]. - Stockholders' equity decreased from $151,970 million to $127,966 million, reflecting a decline of approximately 15.77% [26]. - Cash and cash equivalents increased from $31,693 million to $38,226 million, an increase of about 20.04% [26]. - Total liabilities decreased from $30,533 million to $27,435 million, a decrease of approximately 10.14% [26]. - Total current liabilities decreased from $14,913 million to $12,163 million, a decrease of about 18.43% [26]. - Long-term operating lease liability slightly decreased from $15,620 million to $15,272 million, a reduction of about 2.23% [26]. - Additional paid-in capital increased from $525,934 million to $529,571 million, a growth of about 0.25% [26]. - Accumulated deficit increased from $(374,227) million to $(401,710) million, indicating a worsening of approximately 7.36% [26]. - Accumulated other comprehensive income decreased from $263 million to $105 million, a decline of approximately 60.00% [26].

Product Launch and Revenue - EmrosiTM received FDA approval on November 1, 2024, for treating inflammatory lesions of rosacea, with initial supply available in March 2025 and sales promotion starting in April 2025[92]. - Total net product revenue for Q1 2025 was $13.1 million, a slight increase of 1% from $13.0 million in Q1 2024, driven by $2.0 million from EmrosiTM[99]. - EmrosiTM generated $2.1 million in revenue during its first quarter of commercial launch, offsetting declines in other products like Accutane, which saw a 37% decrease in revenue[99]. - Gross-to-net sales accruals increased to $15.5 million as of March 31, 2025, up from $9.9 million a year earlier, attributed to coupon rebate allowances for EmrosiTM[100]. Financial Performance - Loss from operations improved by 67%, decreasing from $10.1 million in Q1 2024 to $3.3 million in Q1 2025[98]. - The company reported a net loss of $4.1 million for Q1 2025, a 61% reduction compared to a net loss of $10.4 million in Q1 2024[98]. - Operating expenses decreased by 29% from $23.1 million in Q1 2024 to $16.5 million in Q1 2025, primarily due to a 100% reduction in research and development expenses[98]. - Selling, general, and administrative expenses rose by 26% from $8.4 million in Q1 2024 to $10.6 million in Q1 2025[98]. - Interest expense increased by 63% from $548,000 in Q1 2024 to $891,000 in Q1 2025[98]. - Cost of goods sold decreased by $1.2 million, or 20%, to $4.8 million for the three-month period ended March 31, 2025, from $6.0 million for the same period in 2024[101]. Research and Development - Research and development costs were nil in Q1 2025, compared to $7.9 million in Q1 2024, which included Emrosi pre-approval project expenses[103]. - Amortization of acquired intangible assets increased by $0.3 million, or 31%, to $1.1 million for the three-month period ended March 31, 2025, driven by the addition of the Emrosi acquired intangible asset[102]. Cash Flow and Financing - Cash and cash equivalents increased to $21.1 million at March 31, 2025, compared to $20.3 million at December 31, 2024[106]. - Net cash used in operating activities decreased by $2.2 million to $2.8 million for the three-month period ended March 31, 2025, driven by a decrease in net loss[114]. - Net cash flows provided by financing activities increased by $2.0 million to $3.6 million for the three-month period ended March 31, 2025, primarily due to net proceeds from common stock issuances[115]. - Total cash requirements under the SWK Credit Facility include $7.3 million in interest and $25.0 million in principal payments[117]. - The company may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives[108]. Industry and Market Risks - The company operates in a heavily regulated industry, with significant risks related to product development, competition, and market acceptance[89].

Financial Performance - Deere & Company reported a net income of $1.804 billion for Q2 2025, down 24% from $2.370 billion in Q2 2024, with earnings per share decreasing from $8.53 to $6.64[1][5] - Worldwide net sales and revenues decreased by 16% to $12.763 billion for Q2 2025, and by 22% to $21.272 billion for the first six months of the year[2][24] - The company forecasts full-year net income for fiscal 2025 to be in the range of $4.75 billion to $5.50 billion[3] - Production & Precision Agriculture segment net sales fell by 21% to $5.230 billion, with operating profit down 30% to $1.148 billion[6][24] - Small Agriculture & Turf segment net sales decreased by 6% to $2.994 billion, while operating profit remained stable at $574 million[9][24] - Construction & Forestry segment net sales dropped by 23% to $2.947 billion, with operating profit declining 43% to $379 million[13][24] - Financial Services net income for Q2 2025 was flat at $161 million, reflecting less favorable financing spreads[15][24] - Total net income attributable to Deere & Company for the six months ended April 27, 2025, was $2,673 million, down from $4,121 million in the same period of 2024, representing a decline of 35%[27] - Net income attributable to Deere & Company for the three months ended April 27, 2025, was $1,643 million, down 25.5% from $2,208 million in the same period of 2024[35] - Net income attributable to Deere & Company for the six months ended April 27, 2025, was $2,282 million, down 39.2% from $3,751 million in the same period of 2024[37] Sales and Revenue Trends - Net sales for the three months ended April 27, 2025, were $11,171 million, a decrease of 18% compared to $13,610 million in the same period of 2024[27] - For the six months ended April 27, 2025, net sales were $17,980 million, a decline of 25.5% from $24,097 million in the same period of 2024[37] - Total costs and expenses for the three months ended April 27, 2025, were $10,426 million, a decrease of 13.9% from $12,118 million in the same period of 2024[35] Cash Flow and Liquidity - Cash and cash equivalents increased to $7,991 million as of April 27, 2025, compared to $5,553 million as of April 28, 2024[29] - The company reported a net cash provided by operating activities of $568 million for the six months ended April 27, 2025, compared to $944 million in the same period of 2024[31] - Cash flows from operating activities totaled $1,045 million in 2025, down from $3,031 million in 2024, reflecting a significant decline[43] - Cash and cash equivalents at the end of the period increased to $6,352 million in 2025 from $3,839 million in 2024, showing a strong liquidity position[43] Investments and Future Outlook - The company plans to continue significant investments in advanced products and manufacturing capabilities over the next decade[4] - The industry outlook indicates a decline of approximately 30% in large agriculture in the U.S. and Canada, and a 10-15% decrease in small agriculture and turf[18] - The company is navigating challenges from global import tariffs and uncertain trade environments, which may impact future performance[21] Balance Sheet and Assets - Total assets as of April 27, 2025, were $106,303 million, a slight decrease from $107,320 million as of October 27, 2024[29] - Total liabilities decreased to $81,925 million as of April 27, 2025, from $84,395 million as of October 27, 2024[29] - Stockholders' equity for Deere & Company increased to $24.287 billion in April 2025, compared to $22.684 billion in April 2024, marking a growth of about 7.1%[41] Dividends and Shareholder Returns - Dividends declared for the three months ended April 27, 2025, were $1.62 per share, an increase from $1.47 per share in the same period of 2024[27] - Dividends paid increased to $843 million in 2025 from $796 million in 2024, demonstrating a commitment to returning capital to shareholders[43] Other Financial Metrics - Research and development expenses for the three months ended April 27, 2025, were $549 million, slightly down from $565 million in the same period of 2024[27] - Interest expense for the three months ended April 27, 2025, was $784 million, a decrease of 6.2% from $836 million in the same period of 2024[35] - The provision for income taxes for the three months ended April 27, 2025, was $539 million, down from $751 million in the same period of 2024[35] - The provision for credit losses increased to $174 million in 2025 from $131 million in 2024, indicating a rise in expected credit losses[43]

Financial Performance - For the three months ended March 31, 2025, the company reported a net income of $287,896, driven by a change in fair value of warrant liabilities of $548,000 and interest income of $170,992 [202]. - The company experienced a net loss of $3,902,244 for the three months ended March 31, 2024, primarily due to operating and formation costs of $2,408,551 and a change in fair value of warrant liabilities of $2,077,000 [203]. - The Company incurred $50,000 in fees for administrative support services for the three months ended March 31, 2025 [224]. - The Company calculates its earnings per share by allocating net income (loss) pro rata to its Class A and Class B ordinary shares [242]. Cash and Borrowings - As of March 31, 2025, the company had cash held in the Trust Account amounting to $16,086,301, including $1,863,833 of interest expense [210]. - As of March 31, 2025, $2,029,421 was drawn and outstanding under the Second Promissory Note, with an additional $720,579 available for borrowing [207]. - The total amount borrowed under various promissory notes is $2.8 million, with $2.2 million allocated for working capital and $0.6 million for extensions of the Combination Period [218]. - As of March 31, 2025, the Company had outstanding borrowings of $2,029,421 under the promissory note, which bears no interest and is repayable upon the consummation of a Business Combination or liquidation [230]. - The Sponsor has agreed to contribute a loan of $40,443 per month for the first three months of the Third Extension, totaling $121,329, which has been deposited in the Trust Account [232]. - The Company issued the Third Extension Note for up to $161,771.52, with monthly deposits of $53,923.84 into the Trust Account through July 7, 2025 [233]. Business Combination and Extensions - The company has until October 7, 2025, to complete the Nidar Business Combination or another Business Combination, with the possibility of extending this period [190]. - The Company has until October 7, 2025, to complete a Business Combination, or it may seek to extend the Combination Period, subject to shareholder approval [220]. - The company issued the Second Extension Note to the Sponsor for a total amount of $121,329, which was used to make monthly extension payments to extend the Combination Period [195]. - The Company may lack sufficient funds to consummate the Business Combination due to the termination of the Forward Purchase Agreement with the Cartica Funds [227]. Securities and Market Activity - Following the suspension of trading on Nasdaq, the company's securities began trading on the Pink tier of the OTC marketplace, which may result in a less liquid market [198]. - The company completed the sale of 23,000,000 Units at a price of $10.00 per Unit, generating gross proceeds of $230,000,000 during its IPO [205]. - On January 3, 2025, public shareholders redeemed 901,326 Class A ordinary shares for approximately $10.56 million, resulting in a reduction of funds in the Trust Account [194]. - The Company has 27,400,000 warrants issued and outstanding, including 11,500,000 Public warrants classified as Level 1 and 15,900,000 Private Placement Warrants classified as Level 3 [239]. Regulatory and Accounting Standards - The FASB issued ASU Topic 2023-07, effective for fiscal years beginning after December 15, 2023, requiring significant segment expenses disclosures [243]. - ASU 2023-09, effective for fiscal years beginning after December 15, 2024, mandates expanded disclosures of income taxes paid [247]. - The Company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements [249]. - The Company has elected not to opt out of the extended transition period for new or revised financial accounting standards [250]. - The Company is a smaller reporting company and is not required to provide certain market risk disclosures [251]. Investment Commitments - The Cartica Funds agreed to subscribe for up to $30 million in forward purchase shares, but the investment committee has determined not to approve the purchase [227]. - The Company has a contractual obligation to pay the Sponsor an aggregate of $930,000 over eighteen months for administrative support expenses [223].

Financial Performance - For the three months ended March 31, 2025, the company reported a net income of $287,896, driven by a change in fair value of warrant liabilities of $548,000 and interest income of $170,992 [202]. - The company incurred operating and formation costs of $431,096 for the same period, resulting in a net income after expenses [202]. - For the three months ended March 31, 2024, the company experienced a net loss of $3,902,244, which included a change in fair value of warrant liabilities of $2,077,000 and operating costs of $2,408,551 [203]. - The Company calculates its earnings per share by allocating net income (loss) pro rata to its Class A and Class B ordinary shares [242]. Cash and Trust Account - As of March 31, 2025, the company had cash held in the Trust Account amounting to $16,086,301, including $1,863,833 of interest expense [210]. - On January 3, 2025, public shareholders redeemed 901,326 Class A ordinary shares for approximately $10.56 million, resulting in a reduction of funds in the Trust Account [194]. - The total amount deposited in the Trust Account for the year ended March 31, 2025, is $360,000, related to the Second Extension [231]. Business Combination and Extensions - The company has until October 7, 2025, to complete the Nidar Business Combination or another Business Combination, with the possibility of extending this period [190]. - The company issued the Second Extension Note for a total amount of $121,329 to extend the Combination Period through April 7, 2025 [195]. - The Company has until October 7, 2025, to complete a Business Combination, or it may seek to extend the Combination Period, subject to shareholder approval [220]. - As of April 1, 2025, the Company issued the Third Extension Note for up to $161,771.52, with monthly deposits of $53,923.84 through July 7, 2025 [217]. Loans and Financing - The total amount borrowed under various promissory notes is $2.8 million, with $2.2 million allocated for working capital and $0.6 million for extensions of the Combination Period [218]. - The Sponsor has agreed to provide a loan of $40,443 per month for the first three months of the Third Extension, totaling $121,329, which has been deposited in the Trust Account [216]. - The Company may convert up to $2 million of Working Capital Loans into warrants at a price of $1.00 per warrant [219]. Market and Trading Conditions - Following the suspension of trading on Nasdaq, the company's securities began trading on the Pink tier of the OTC marketplace, which may result in a less liquid market [198]. - The Company has a liquidity condition that raises substantial doubt about its ability to continue as a going concern for the next twelve months [222]. Underwriting and Fees - The underwriters received a cash underwriting discount of $4.6 million and a deferred fee of $8.05 million, which will only be payable if a business combination is completed [226]. Regulatory and Reporting Standards - In November 2023, the FASB issued ASU Topic 2023-07, which requires disclosures of significant segment expenses and other segment items included in the reported measure of segment profit or loss [243]. - ASU 2023-07 will be effective for fiscal years beginning after December 15, 2023, with early adoption permitted [246]. - In December 2023, the FASB issued ASU Topic 2023-09, which requires expanded disclosures of income taxes paid and incremental income tax information within the rate reconciliation [247]. - The Company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements [249]. - The Company has elected not to opt out of the extended transition period under the JOBS Act, allowing it to adopt new or revised standards at the same time as private companies [250]. - The Company is a smaller reporting company and is not required to provide certain market risk disclosures [251]. Warrants - The Company has 27,400,000 warrants issued and outstanding, including 11,500,000 Public warrants classified as Level 1 [239].

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 For the Three Months Ended March 31, 2025 (Unaudited and Expressed in US Dollars) POET TECHNOLOGIES INC. POET TECHNOLOGIES INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Expressed in US Dollars) (Unaudited) | | | March 31, | | December 31, | | --- | --- | --- | --- | --- | | | | 2025 | | 2024 | | Assets | | | | | | Current | | | | | | Cash and cash equivalents (Note 2) | $ | 15,900,425 | $ | 37,143,759 | | Short-term inv ...

Financial Performance - The company reported a net income of $1,601,840 for the three months ended March 31, 2025, consisting of $1,792,415 in investment income and a loss from operations of $190,575 [102]. - Cash used in operating activities for the three months ended March 31, 2025, was $391,993, with net income affected by interest earned on investments and operational costs [105]. Initial Public Offering (IPO) - The Initial Public Offering (IPO) generated gross proceeds of $287,500,000 from the sale of 28,750,000 Units at $10.00 per Unit, along with an additional $9,227,270 from the sale of 922,727 Private Placement Units [103]. - The company incurred $16,427,868 in IPO-related costs, including $15,812,500 in underwriting fees [104]. Investments and Financial Position - As of March 31, 2025, the company had investments held in the Trust Account totaling $290,729,915, compared to $0 as of December 31, 2024 [106]. - The company has no long-term debt or off-balance sheet arrangements as of March 31, 2025 [110]. - The company intends to use substantially all funds in the Trust Account to complete its Business Combination and for working capital of the target business [106]. Obligations and Financing Needs - The company has a contractual obligation to pay an affiliate of an executive officer a monthly fee of $25,000 for office space and administrative support [111]. - The company may need additional financing to complete its Business Combination or if a significant number of Public Shares are redeemed [109]. Accounting Standards - The company has adopted new accounting standards effective July 2, 2024, which may impact segment reporting disclosures [118].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42503 K&F GROWTH ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-37685 PAVMED INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-1214177 (State or Other Jurisdic ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission File Number 001-42285 Foxx Development Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 99-5119494 (State or other juri ...